- Home
- SER vs INMB Comparison
SER vs INMB Comparison
Compare SER & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- INMB
- Stock Information
- Founded
- SER 2017
- INMB 2015
- Country
- SER United States
- INMB United States
- Employees
- SER N/A
- INMB N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- INMB Health Care
- Exchange
- SER Nasdaq
- INMB Nasdaq
- Market Cap
- SER 55.2M
- INMB 49.2M
- IPO Year
- SER 2018
- INMB 2019
- Fundamental
- Price
- SER $5.00
- INMB $1.83
- Analyst Decision
- SER Strong Buy
- INMB Hold
- Analyst Count
- SER 2
- INMB 3
- Target Price
- SER $13.00
- INMB $4.30
- AVG Volume (30 Days)
- SER 43.2K
- INMB 361.9K
- Earning Date
- SER 11-11-2025
- INMB 10-30-2025
- Dividend Yield
- SER N/A
- INMB N/A
- EPS Growth
- SER N/A
- INMB N/A
- EPS
- SER N/A
- INMB N/A
- Revenue
- SER $130,000.00
- INMB $50,000.00
- Revenue This Year
- SER $134.46
- INMB $264.29
- Revenue Next Year
- SER N/A
- INMB $9,819.61
- P/E Ratio
- SER N/A
- INMB N/A
- Revenue Growth
- SER N/A
- INMB 19.05
- 52 Week Low
- SER $3.81
- INMB $1.71
- 52 Week High
- SER $7.92
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- SER 48.12
- INMB 44.66
- Support Level
- SER $4.60
- INMB $1.73
- Resistance Level
- SER $5.01
- INMB $1.89
- Average True Range (ATR)
- SER 0.24
- INMB 0.10
- MACD
- SER -0.02
- INMB 0.00
- Stochastic Oscillator
- SER 57.97
- INMB 37.04
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.